# A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct05252364/  
OnCo record `nct05252364` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of HP518 run by Hinova Pharmaceuticals Aus Pty Ltd, completed.

## Summary

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT05252364 by Hinova Pharmaceuticals Aus Pty Ltd, with 22 participants enrolled, started 2021-12-14. Conditions recorded: Metastatic Castration-resistant Prostate Cancer. Interventions recorded: HP518 - Dose Escalation and HP518 - Dose expansion.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05252364
- Phase: 1
- Setting: A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Hinova Pharmaceuticals Aus Pty Ltd
- Enrolled: 22

## Sources

- ClinicalTrials.gov NCT05252364: https://clinicaltrials.gov/study/NCT05252364

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- drugs: [HP518](https://onco.cc/drugs/hp518/)
- companies: [Hinova Pharmaceuticals](https://onco.cc/companies/hinova-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct05252364.json